Gender biases and hate speech: Promoters and targets in the Argentinean political context.

Hate speech found in social media a place to flourish. In the Argentinean context, new right-wing parties have disrupted the political arena, winning the elections of 2023. Many of these new right-wing figures grew in popularity due to their use of social media, on a background of increasing political violence.

Computational and digital analyses in the INSPIRE mouse cohort to define sex-specific functional determinants of biological aging.

Biological age, which reflects the physiological state of an individual, offers a better predictive value than chronological age for age-related diseases and mortality. Nonetheless, determining accurate functional features of biological age remains challenging due to the multifactorial nature of aging. Here, we established a unique mouse cohort comprising 1576 male and female outbred SWISS mice subjected or not to high-fat, high-sucrose diet to investigate multiorgan/system biological aging throughout adulthood.

Introducing all-inkjet-printed microneedles for in-vivo biosensing.

Microneedles are mainly used for pain-free drug administration and in biosensing for wearable systems. They are also promising for fields such as agronomy for precision farming, but their fabrication is not straightforward, often requiring expensive equipment and cleanroom protocols, being unsuitable for mass production. Here, we report a new and simple method for the scalable fabrication of all-inkjet-printed conductive microneedles based on silver nanoparticles (extensible to any other metallic nanoparticle ink) and a simple example of their application for monitoring the electrochemical properties of plants.

Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial.

Purpose: To investigate whether intermittent treatment after an induction phase of first-line schedule of fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus panitumumab (PAN) prevents or delays the onset of resistance and improves safety and compliance with treatment in patients with unresectable / wild-type (wt) metastatic colorectal cancer (mCRC).

Patients And Methods: IMPROVE (ClinicalTrials.gov identifier: NCT04425239) was an open-label, multicenter, randomized phase II noncomparative trial.